VOIS植入物治疗单侧声带麻痹患者的初步临床结局
这项前瞻性病例系列研究在单个三级转诊中心纳入13例单侧声带麻痹患者,在局部麻醉下接受VOIS植入联合喉内移术。术后6个月,VHI-30和最长发声时间(MPT)较术前显著改善,GRBAS各分项评分均下降,全部患者声门闭合改善,5例接受术后调整,未观察到术中或术后并发症。作者认为VOIS植入是安全的手术,嗓音结局良好,术后调整可顺利进行。
要点
- 13例单侧声带麻痹患者局部麻醉下接受VOIS植入联合喉内移术。
- 术后6个月VHI-30从术前均值75.0±22.9降至20.6±19.7,MPT从2.7±2.1 s升至6.3±4.0 s。
- 全部13例声门闭合改善,5例接受术后调整,未观察到术中或术后并发症。
核心结论
- 作者认为APrevent® VOIS植入是安全的手术,嗓音结局良好。
- 作者认为术后调整可顺利进行,以优化嗓音质量和声门闭合。
- 证据等级为3级。
研究设计与样本
- 前瞻性病例系列研究,在单个三级转诊中心开展。
- 13例单侧声带麻痹患者接受VOIS植入联合喉内移术,局部麻醉下进行。
- 术前及术后1周、7周、6个月测量声门效率(最长发声时间MPT)、嗓音质量(GRBAS评分和声学参数)及自评嗓音相关障碍(VHI-30)。
- 通过柔性视频喉镜依据Södersten和Lindestad分类评估声带闭合类型,采用Wilcoxon符号秩检验分析。
主要发现
- 术后6个月VHI-30从术前均值75.0±22.9改善至术后均值20.6±19.7。
- 术后6个月MPT从术前均值2.7±2.1 s改善至术后均值6.3±4.0 s。
- 术后6个月GRBAS各分项均值从术前Gpreop=2.7、Rpreop=2.6、Bpreop=2.6、Apreop=2.2、Spreop=2.0改善至Gpostop=0.3、Rpostop=0.3、Bpostop=0.2、Apostop=0.2、Spostop=0.3。
- 全部13例患者声门闭合改善。
- 5例患者接受术后调整以优化嗓音质量和声门闭合。
临床怎么用
- 原文结论指出APrevent® VOIS植入是安全的手术,嗓音结局良好。
- 原文结论指出术后调整可顺利进行,以优化嗓音质量和声门闭合。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Evaluation of the clinical outcomes after 6 months of treatment with a novel adjustable implant, the APrevent® Vocal-Implant-System (VOIS), in conjunction with medialization thyroplasty (MT) in patients with unilateral vocal fold paralysis. STUDY DESIGN: Prospective case series study at single tertiary referral center. METHODS: Preoperative and 1 week, 7 weeks, and 6 months postoperative glottal efficiency (maximum phonation time [MPT]), voice quality (including GRBAS-scores and acoustic parameters) and self-perceived voice-related handicap (voice handicap index [VHI-30]) were measured and analyzed, whereas type of vocal fold closure was evaluated and determined by flexible videolaryngoscopy based on Södersten and Lindestad classification (Wilcoxon signed-rank test). RESULTS: Thirteen patients underwent MT with VOIS under local anesthesia. Six months after surgery, the VHI-30 and MPT had improved from a preoperative mean of 75.0 ± 22.9 and 2.7 ± 2.1 s to a postoperative mean of 20.6 ± 19.7 and 6.3 ± 4.0 s, respectively. The mean GRBAS score improved from preoperative scores of Gpreop = 2.7, Rpreop = 2.6, Bpreop = 2.6, Apreop = 2.2, and Spreop = 2.0 to Gpostop = 0.3, Rpostop = 0.3, Bpostop = 0.2, Apostop = 0.2, and Spostop = 0.3 at 6 months postoperatively. Improved glottal closure was achieved in all patients (n = 13). Five patients received postoperative adjustment for the optimization of voice quality and glottal closure. No intra- or postoperative complications were observed. Significant improvements in acoustic parameters, including percentage jitter, percentage shimmer, and signal-to-noise ratio, were also observed after MT. All results were statistically significant (P < .05, Cohen's d > .8). CONCLUSIONS: APrevent® VOIS-Implantation is a safe procedure with good voice outcomes. Postoperative adjustments can be performed smoothly to optimize voice quality and glottal closure. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:1622-1629, 2022.
引用
- Hsieh LC, Chen CK, Chang CW, et al. Preliminary Clinical Outcomes of VOIS-Implant in Patients With Unilateral Vocal Fold Paralysis. Laryngoscope. 2021. PMID: 34817072. doi:10.1002/lary.29958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。